RT-002 is a Protein owned by Revance Therapeutics, and is involved in 18 clinical trials, of which 16 were completed, and 2 are ongoing.

RT-002 (botulinum toxin type-A) acts by targeting synaptosomal associated protein 25 and blocks neuromuscular transmission by binding to acceptor sites on motor or sympathetic nerve terminals, entering the nerve terminals and inhibiting the release of acetylcholine. This inhibition occurs as the neurotoxin cleaves SNAP-25, a protein integral to the successful docking and release of acetylcholine from vesicles situated within nerve endings. Thus the drug candidate helps in the treatment of disease.

The revenue for RT-002 is expected to reach a total of $2bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the RT-002 NPV Report.

RT-002 was originated by Botulinum Toxin Research Associates and is currently owned by Revance Therapeutics.

RT-002 Overview

RT-002 is under development for the treatment of spasmodic torticollis (cervical dystonia), upper limb spasticity voice disorders, spasmodic dysphonia in after stroke or traumatic brain injury. It is administered by intramuscular route and a unspecified indication. The drug candidate is an injectable neurotoxin, purified botulinum toxin type A that targets synaptosomal-associated protein 25. It is developed based on TransMTS peptide technology.

It was under development for the treatment of plantar fasciitis and chronic migraine.

Revance Therapeutics Overview

Revance Therapeutics is a biotechnology company that focuses on the development, manufacturing and marketing novel botulinum toxin products. It is investigating its lead candidate, daxibotulinumtoxinA, a topical gel formulation as a needle-free approach for a wide range of therapeutic and aesthetic indications, such as facial wrinkles, chronic migraine, and muscle disorders. Through the acquisition of HintMD, the company uses it platform to engage in the smart payment solution to process payments for their patients and provides subscription and pay-over-time solutions that support practices for the aesthetic treatment plans. The company is also advancing daxibotulinumtoxinA for injection (DAXI), an injectable formulation of botulinum toxin for the treatment of glabellar lines, cervical dystonia and plantar fasciitis. It employs its proprietary peptide excipient technology to advance the development of its novel neuromodulators portfolio. Revance Therapeutics is headquartered in Nashville, Tennessee, the US.

The company reported revenues of (US Dollars) US$77.8 million for the fiscal year ended December 2021 (FY2021), compared to a revenue of US$15.3 million in FY2020. The operating loss of the company was US$274.7 million in FY2021, compared to an operating loss of US$273.2 million in FY2020. The net loss of the company was US$281.3 million in FY2021, compared to a net loss of US$282.1 million in FY2020. The company reported revenues of US$29 million for the third quarter ended September 2022, an increase of 2.3% over the previous quarter.

Quick View – RT-002

Report Segments
  • Innovator
Drug Name
  • RT-002
Administration Pathway
  • Intramuscular
  • Parenteral
  • Topical
Therapeutic Areas
  • Central Nervous System
  • Ear Nose Throat Disorders
  • Musculoskeletal Disorders
  • Undisclosed
Key Companies
Highest Development Stage
  • Pre-Registration

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.